News & Events
- November 29, 2023
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
- September 12, 2023
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
- June 7, 2023
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
- May 3, 2023
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
- April 26, 2023
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board
- April 3, 2023
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
- March 31, 2023
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
- February 15, 2023
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
- February 14, 2023
Entera Bio to Participate in the SVB Securities Global Biopharma
Conference
- October 6, 2022
